Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of purchasers of American Depositary Receipts ("ADRs") of GSK plc between February 5, ...

CFRA analyst Wan Nurhayati revised the price target for GlaxoSmithKline (NYSE:GSK) shares, reducing it to $40.00 from the ...

Revenue for Arexvy and Abrysvo fell sharply year over year in the fourth quarter due to narrower U.S. guidelines for their use.

While vaccine sales dropped, GSK raised its revenue guidance for 2031 with speciality medicines expected to drive that growth ...

Q4 2024Management ViewCEO Dame Emma Walmsley highlighted that GSK achieved 8% sales growth in 2024, reaching over ...

Even as GSK’s RSV vaccine launch hits a serious slowdown, the British pharma has dialed up its long-term sales guidance once ...

GSK plc GSK reported fourth-quarter 2024 core earnings of 59 cents per American depositary share (ADS), which beat the Zacks ...

Markets have hardly recovered from the DeepSeek shock and have just met trade tariff headwinds. Nonetheless, these stocks are ...

London stocks were still a touch higher by midday on Wednesday as investors continued to mull the impact of Trump’s trade war ...

Mark Hartley weighs up the growing potential in GSK as its share price makes rare gains following a promising set of results.

GSK plans to buy back $2.50 billion in shares and raised its midterm sales target, citing promising pipeline developments.

The Shanghai Composite fell 0.7% in afternoon trade. It was the first time the Shanghai market re-opened after the Chinese New Year break. The Hang Seng Index in Hong Kong was down 0.9%. Tokyo's ...